Prevention of coronary heart disease with aspirin and clopidogrel: Efficacy, safety, costs and cost-effectiveness

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 3, 2004, Pages 493-503

  Ho, Wai Khoon ^a   Hankey, Graeme J ^a,b   Eikelboom, John W ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antiplatelet therapy; Aspitin; Clopidogrel; Coronary heart disease; Pharmacoeconomics

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO;

BRAIN HEMORRHAGE; CAUSE OF DEATH; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; RASH; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; ST SEGMENT ELEVATION; STROKE; THROMBOCYTE; UPPER GASTROINTESTINAL BLEEDING; VASCULAR DISEASE;

ASPIRIN; CLINICAL TRIALS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 1542400529     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.3.493     Document Type: Review

References (56)

1. BUJA LM, MCALLISTER HA: Anatomic abnormalities and pathogenesis. In: Cardiovascular Medicine (2nd edn). Willerson JT, Cohn JN (Eds), Churchill Livingstone, Philadelphia, USA (2000):503-520.
2. RUSSELL MW, HUSE DM, DROWNS S, HAMEL EC, HARTZ SC: Direct medical costs of coronary artery disease in the United States. Am. J. Cardiol. (1998) 81:1110-1115.
3. AMERICAN HEART ASSOCIATION: Heart disease and stroke statistics. American Heart Association, Dallas, TX, USA (2002):40.
4. EISENSTEIN EL, SHAW LK, ANSTROM KJ et al.: Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med. Care (2001) 39:824-835.
5. SLOSS EM, WICKSTROM SL, MCCAFFREY DF et al.: Direct medical costs attributable to acute myocardial infarction and ischaemic stroke in cohorts with atherosclerotic conditions. Circulation (2001) 106(Suppl. II):3746.
6. DOBSON AJ, ALEXANDER HM, HELLER RF, MALCOLM JA, STEELE PL: Trends in ischaemic heart disease in the Hunter Region of New South Wales 1985-1989. Med. J. Aust. (1991) 155:599-608.
7. HUNINK MGM, GOLDMAN L, TOSTESON ANA et al.: The recent decline in mortality form coronary heart disease, 1980-1990. JAMA (1997) 277:535-542.
8. KIRCHHOFF M, DAVIDSEN M, BRØNNUM-HANSEN H et al.: Incidence of myocardial infarction in the Danish MONICA population 1982-1991. Inter J. Epidemiol. (1999) 28:211-218.
9. KOSTIS JB, WILSON AC, LACY CR et al.: Tune trends in the occurrence and outcome of acute myocardial infarction and coronary heart disease between 1986 and 1996 (A New Jersey statewide study). Am. J. Cardiol. (2001) 88:837-841.
10. DAVIDSEN M, BRØNNUM-HANSEN H, JØRGENSEN T et al.: Trends in incidence, case-fatality and recurrence of myocardial infarction in the Danish MONICA population 1982-1991. Eur. J. Epidemiol. (2001) 17:1139-1145.
11. MARQUES-VIDAL P, RUIDAVETS J-B, CAMBOU J-P, FERRIÈRES J: Incidence, recurrence, and case fatality rates for myocardial infarction in southwestern France, 1985 to 1993. Heart (2000) 84:171-175.
12. MURRAY CJL, LOPEZ AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 349:1269-1276.
13. THE WORLD HEALTH REPORT: Making a Difference. World Health Organization, Geneva (1999).
14. YUSUF S, REDDY S, ÔUNPUU S, ANAND S: Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation (2001) 104:2746-2753.
15. BONOW RO, SMAHA LA, SMITH SC, MENSAH GA, LENFANT C: World Heart Day 2002. The international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation (2002) 106:1602-1605.
16. KELLY DT: Paul Dudley White International lecture. Our future society. A global challenge. Circulation (1997) 95:2459-2464.
17. HAYDEN M, PIGNONE M, PHILLIPS C, MULROW C: Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. (2002) 136:161-172.
18. ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71-96.
19. CAPRIE STEERING COMMITTEE. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329-1339.
20. BHATT DL, HIRSCH AT, RINGLEB PA, HACKE W, TOPOL EJ: Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE trial investigators. Am. Heart J. (2000) 140:67-73.
21. BHATT DL, MARSO SP, HIRSCH AT, RINGLEB PA, HACKE W, TOPOL EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am. J. Cardiol. (2002) 90:625-628.
22. BHATT DL, CHEW DP, HIRSCH AT, RINGLEB PA, HACKE W, TOPOL EJ: Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation (2001) 103:363-368.
23. THE CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS TRIAL INVESTIGATORS: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345:494-502.
24. JNEID H, BHATT DL, CORTI R, BADIMON JJ, FUSTER V, FRANCIS GS: Aspirin and clopidogrel in acute coronary syndromes: Therapeutic insights from the CURE study. Arch. Intern. Med. (2003) 163:1145-1153.
25. MEHTA SR, YUSUF S, PETERS RJG et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet (2001) 358:527-533.
26. STEINHUBL SR BERGER PB, MANN JT et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA (2002) 288:2411-2420.
27. HANKEY GJ, SUDLOW CLM, DUNBABIN DW: Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systemic review of the evidence from randomized trials. Stroke (2000) 31:1779-1784.
28. MEDICAL ECONOMICS STAFF: Drug topics red book. Medical Economics, Montvale, NJ, USA (2000).
29. GASPOZ JM, COXSON PG, GOLDMAN PA et al.: Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N. Engl. J. Med. (2002) 346:1800-1806.
30. ANNEMANS L, LAMOTTE M, LEVY E, LENNE X: Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J. Med. Economics (2003) 6:55-68.
31. EDELSON JT, TOSTESON AN, SAX P: Cost-effectiveness of misoprostol for prophylaxis against non-steroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA (1990) 264:41-47.
32. MANDELBLATT JS, FRYBACK DG, WEINSTEIN MC, RUSSELL LB, GOLD MR: Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J. Gen. Intern. Med. (1997) 12:551-558.
33. MARISSAL JP, SELKE B, LEBRUN T: Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. Pharmacoeconomics (2000) 18:185-200.
34. CHAMBERS M, HUTTON J, GLADMAN J: Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Pharmacoeconomics (1999) 16:577-593.
35. GORELICK PB, BORN GVR, D'AGOSTINO RB, HANLEY DF Jr, MOYE L, PEPINE CJ: Therapeutic benefit: Aspirin revisited in light of the introduction of clopidogrel. Stroke (1999) 30:1716-1721.
36. ANNEMANS L, LINDGREN P, FREI A, GABRIEL S, SPIESSER J: Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: A five European countries analysis. European Society of Cardiology Annual Scientific Meeting. Vienna, Austria (2003) (Abstract P1302).
37. ANNEMANS L, LINDGREN P, FREI A, GABRIEL S, SPIESSER J: Cost-effectiveness analysis of clopidogrel in patients with unstable coronary artery disease undergoing percutaneous coronary interventions (PCI): A five European countries analysis. European Society of Cardiology Annual Scientific Meeting. Vienna, Austria (2003) (Abstract P1300).
38. LAMY A, CHROLAVICIUS S, GAFNI A et al.: The cost-effectiveness of the use of clopidogrel in acute coronary syndromes based upon the CURE study. Circulation (2002) 106(Suppl. II):3721.
39. MEHTA SR, WEINTRAUB WS, JONSSON B et al.: Incremental cost-effectiveness of early and long term clopidogrel in patients undergoing PCI in the CURE trial: The PCI-CURE Economic Analysis. 52nd Annual Scientific Sessions of the American College of Cardiology. Chicago, USA (2003) (Abstract 1171-112).
40. FRANZOSI MG, FOR THE GISSI INVESTIGATORS: Ten year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 Study. Circulation (1998) 98:2659-2665.
41. LEVY E, GABRIEL S, CARITA P, DINET J: An economic evaluation of clopidogrel in secondary prevention of ischaemic events: High risk populations. Value Health (2002) 5:477-478 (PCV1).
42. SARASIN FP, GASPOZ JM, BOUNAMEUAX H: Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischaemic attack. Arch. Intern. Med. (2000) 160:2773-2778.
43. LINDGREN P, JONSSON B: Modelling the cost-effectiveness of clopidogrel in acute coronary syndromes without ST-segment elevation in Sweden. 52nd Annual Scientific Sessions of the American College of Cardiology. Chicago, USA (2003) (Abstract 885-2).
44. VAN HOUT B: Cost-effectiveness analysis of antithrombotic treatment with clopidogrel in patients with myocardial infarction, stroke and peripheral arterial disease in the Netherlands. ISPOR Congress, Barcelona, Spain (2003).
45. DE LEMOS JA, MCGUIRE DK: Aspirin, clopidogrel, or both for secondary prevention of coronary disease. N. Engl. J. Med. (2003) 348:561.
46. POSTMA MJ, HEIJNEN ML, BEUTELS P et al.: Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost-effectiveness analysis. Ned. Tijdschr. Geneeskd (2002) 146:855-889.
47. YOUNG A, PLOSKER GL: Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. Pharmacoeconomics (2001) 19:1227-1259.
48. BERTHELOT JM, WILL BP, EVANS WK et al.: Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J. Natl. Cancer Inst. (2000) 92:1321-1329.
49. MARK DB, HARRINGTON RA, LINCOFF AM et al.: Cost-effectiveness of platelet Glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation (2000) 101:366-371.
50. GARBER AM, PHELPS CE: Economic foundations of cost-effectiveness analysis. J. Health Economics (1997) 16:1-31.
51. WHO COMMISSION ON MACROECONOMICS AND HEALTH: Macroeconomics and Health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. WHO, Geneva, Switzerland (2001).
52. MURRAY CJ, LAUER JA, HUTUBESSY RCW et al.: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular risk. Lancet (2003) 361:717-725.
53. MULS E, VAN GANSE E, CLOSON MC: Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: Comparison between Belgium and the United States of a projected risk model. Atherosclerosis (1998) 137(Suppl.): S111-S116.
54. BROWN AID, GARBER AM: A concise review of the cost-effectiveness of coronary heart disease prevention. Med. Clin. N. Am. (2000) 84:279-297.
55. CARO JJ, MIGLIACCIO-WALLE K: Generalising the results of clinical trials to actual practice: The example of clopidogrel therapy for the prevention of vascular events. Am. J. Med. (1999) 107:568-572.
56. LIEW D, MCNEIL JJ, PEETERS A, LIM SS, VOS T: Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. Med. J. Aust. (2002) 177:364-367.